摘要
目的探讨孟鲁司特联合盐酸氨溴索治疗难治性哮喘的临床效果。方法将60例难治哮喘患者随机分为2组。联合用药组在GINA方案基础上服用孟鲁司特联合盐酸氨溴索,对照组给予GINA方案治疗。结果治疗两周后联合用药治疗组患者的发作次数、平均发作时间均显著低于常规用药组(P<0.05);肺功能改善优于常规用药组(P<0.05);有效率高于常规用药组(P<0.05)。结论孟鲁司特联合盐酸氨溴索治疗难治性哮喘效果较为理想,且安全性高。
Objective To investigate the effect of montelukast （Singulair） combined with ambroxol hydrochloride in the treatment of refractory asthma. Methods 60 patients with refractory asthma were randomly divided into 2 groups. Patients in the treatment group took montelukast （Singulair） and ambroxol hydrochloride on the basis of GINA. In the control group, patients were given GINA treatment. Results After two weeks of treatment, the number of episodes of the patients in the combination therapy group were signifieantly lower than that in the conventional treatment group （ P 〈 0. 05 ） ; the lung function improvement was superior to the conventional treatment group （ P 〈 0. 05 ） ; the effictive rate of treatment group was higher than that of conventional treatment group （ P 〈 0. 05 ）. Conclusions Monte- lukast joint hydrochloride ambroxol to treat refractory asthma is ideal and safe, which is a viable option in the treatment of refractory asth-
出处
《临床肺科杂志》
2012年第10期1781-1782,共2页
Journal of Clinical Pulmonary Medicine
关键词
孟鲁司特
盐酸氨溴索
难治性哮喘
疗效
Montelukast
Ambroxol Hydrochloride
refractory asthma
efficacy
